Reduced pulmonary function is associated with enhanced inflammation and tissue inhibitor of metalloproteinase 1 concentration in the bronchoalveolar lavage fluid of patients with lung parenchymal sarcoidosis

Kurume Medical Journal

Volumn 55, Issue 1-2, 2008, Pages 13-17

  Shimada, Akiko ^a   Koga, Takeharu ^a,b   Oshita, Yuichi ^a   Hanada, Mikiko ^a   Nagafuchi, Yoshiro ^a   Aizawa, Hisamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Asakura Medical Association Hospital   (Japan)

Author keywords

Lung parenchymal disease; Sarcoidosis

Indexed keywords

CARBON MONOXIDE; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BLOOD GAS ANALYSIS; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG SARCOIDOSIS; MALE; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; PROTEIN FUNCTION; REFERENCE VALUE; SPIROMETRY;

EID: 56749157603     PISSN: 00235679     EISSN: 18812090     Source Type: Journal    
DOI: 10.2739/kurumemedj.55.13     Document Type: Article

References (18)

1. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr. et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-1889.
2. James DG, Neville E, and Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci 1976; 278:321-334.
3. American Thoracic Society. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755.
4. Agostini C, Cabrelle A, Calabrese F, Bortoli M, Scquizzato E et al. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med 2005; 172:1290-1298.
5. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152:1107-1136.
6. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995; 152:2185-2198.
7. Keogh BA, Hunninghake GW, Line BR, and Crystal RG. The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Respir Dis 1983; 128:256-265.
8. Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 2004; 9:458-465.
9. MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720-735.
10. Henry MT, McMahon K, Mackarel AJ, Prikk K, Sorsa T et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J 2002; 20:1220-1227.
11. Gonzalez AA, Segura AM, Horiba K, Qian S, Yu ZX et al. Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immuno-histochemical study. Hum Pathol 2002; 33:1158-1164.
12. Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000; 279:L562-L574.
13. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW et al. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997; 158:2327-2333.
14. Choi KH, Lee HB, Jeong MY, Rhee YK, Chung MJ et al. The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest 2002; 121:1478-1485.
15. Schoenfeld N, Schmitt M, Remy N, Ellensohn P, Loddenkemper R et al. Activation of bronchoalveolar lavage T lymphocytes and clinical, functional and radiological features in sarcoidosis. Sarcoidosis 1995; 12:135-139.
16. Xaubet A, Agusti C, Roca J, Picado C, and Rodriguez-Roisin R. BAL lymphocyte activation antigens and diffusing capacity are related in mild to moderate pulmonary sarcoidosis. Eur Respir J 1993; 6:715-718.
17. Fireman E, Kraiem Z, Sade O, Greif J, and Fireman Z. Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous diseases. Clin Exp Immunol 2002; 130:331-337.
18. Hance AJ, Basset F, Saumon G, Danel C, Valeyre D et al. Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis. Ann N Y Acad Sci 1986; 465:643-656.